Fig. 1: Time to PSA50, PSA90 and undetectable PSA ( < 0.2 ng/ml) by starting treatment in patients with mHSPC – Kaplan-Meier method. | Prostate Cancer and Prostatic Diseases

Fig. 1: Time to PSA50, PSA90 and undetectable PSA ( < 0.2 ng/ml) by starting treatment in patients with mHSPC – Kaplan-Meier method.

From: Survival outcomes of apalutamide as a starting treatment: impact in real-world patients with metastatic hormone sensitive prostate cancer (OASIS)

Fig. 1

AAP abiraterone acetate plus prednisone, ADT androgen deprivation therapy, APA apalutamide, DTX docetaxel, ENZ enzalutamide, mHSCP metastatic hormone-sensitive prostate cancer, PSA50/PSA90 50%/90% decline in PSA from baseline, Undetectable PSA, ≤0.2 ng/ml.

Back to article page